A BILL 
To provide for a study on the current and historical produc-
tion of drugs in the United States and in foreign coun-
tries, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Improving the Amer-
4
ican Drug Supply Chain Act of 2020’’. 
5
23:13 Oct 31, 2020
H8588
2 
•HR 8588 IH
SEC. 2. STUDY AND REPORTING ON DOMESTIC AND FOR-
1
EIGN PRODUCTION. 
2
(a) IN GENERAL.—The Secretary of Health and 
3
Human Services shall enter into an agreement with the 
4
National Academies of Sciences, Engineering, and Medi-
5
cine (referred to in this section as the ‘‘National Acad-
6
emies’’) under which, not later than 24 months after the 
7
date of enactment of this Act, the National Academies 
8
will— 
9
(1) study the current and historical production 
10
of drugs and key ingredients thereof (including ac-
11
tive pharmaceutical ingredients) in the United 
12
States and in foreign countries; 
13
(2) formulate recommendations for promoting 
14
increased production of drugs and key ingredients 
15
thereof (including active pharmaceutical ingredients) 
16
in the United States; and 
17
(3) in a manner that does not compromise na-
18
tional security or disclose trade secrets or other con-
19
fidential commercial information that is subject to 
20
section 552(b)(4) of title 5, United States Code, or 
21
section 1905 of title 18, United States Code, submit 
22
a report to the Congress on— 
23
(A) the findings and conclusions of the 
24
study under paragraph (1); and 
25
23:13 Oct 31, 2020
H8588
3 
•HR 8588 IH
(B) the recommendations under paragraph 
1
(2). 
2
(b) STUDY TOPICS.—The study pursuant to sub-
3
section (a)(1) shall include— 
4
(1) evaluation of— 
5
(A) the extent to which production of 
6
drugs for use in the United States and key in-
7
gredients thereof (including active pharma-
8
ceutical ingredients) takes place in the United 
9
States; and 
10
(B) the extent to which such production 
11
takes place in foreign countries; 
12
(2) identification of the foreign countries in 
13
which such production takes place; 
14
(3) evaluation of historical changes in the coun-
15
tries in which such production takes place; 
16
(4) determination of the reasons why such pro-
17
duction takes place in foreign countries, including 
18
why such production takes place in particular for-
19
eign countries, including consideration of— 
20
(A) the reasons for historical migration of 
21
such production to foreign countries, or from 
22
foreign countries to other foreign countries or 
23
the United States; 
24
23:13 Oct 31, 2020
H8588
4 
•HR 8588 IH
(B) economic factors, including economic 
1
impediments to domestic production and incen-
2
tives for foreign production; and 
3
(C) regulatory, intellectual property, inter-
4
national trade, and other legal and policy fac-
5
tors; and 
6
(5) evaluation of the benefits of redundancies in 
7
the supply chain of drugs in the United States in 
8
the event of a public health emergency. 
9
(c) RECOMMENDATIONS.—The agreement under sub-
10
section (a) shall— 
11
(1) provide for inclusion in the recommenda-
12
tions under subsection (a)(2) of measures (which 
13
may include statutory, regulatory, and other policy 
14
changes) that should be taken— 
15
(A) to encourage the domestic production 
16
of drugs for use in the United States and key 
17
ingredients thereof (including active pharma-
18
ceutical ingredients); or 
19
(B) to otherwise reduce the risks to the 
20
availability of drugs in the United States in the 
21
event of a public health emergency; and 
22
(2) require consideration, in developing such 
23
recommendations, of— 
24
23:13 Oct 31, 2020
H8588
5 
•HR 8588 IH
(A) factors affecting the production of 
1
drugs, including— 
2
(i) access to skilled labor; 
3
(ii) the cost of raw materials, the cost 
4
of energy, and related costs; 
5
(iii) taxes and other incentives; and 
6
(iv) the effects of regulations; and 
7
(B) the costs and consequences of imple-
8
menting, or failing to implement, each such rec-
9
ommendation. 
10
(d) INPUT.—The agreement under subsection (a) 
11
shall require— 
12
(1) consideration of input from the Department 
13
of Health and Human Services, the Department of 
14
Commerce, and, as appropriate, other Federal agen-
15
cies; and 
16
(2) consultation with relevant stakeholders, 
17
which— 
18
(A) may include conducting public meet-
19
ings and other forms of engagement, as appro-
20
priate; 
21
(B) shall include consultation with experts 
22
in— 
23
(i) the manufacturing of drugs; 
24
03:59 Nov 04, 2020
H8588
6 
•HR 8588 IH
(ii) pharmaceutical industry business 
1
and economics; 
2
(iii) drug purchasing, pricing, and re-
3
imbursement; 
4
(iv) regulatory and intellectual prop-
5
erty issues affecting drug manufacturing; 
6
(v) economics; 
7
(vi) international trade policy; and 
8
(vii) emergency planning; and 
9
(C) may include consultation with other 
10
entities with experience in drug manufacturing 
11
and pricing, as appropriate. 
12
(e) DEFINITIONS.—In this section, the term ‘‘drug’’ 
13
has the meaning given such term in section 201 of the 
14
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321). 
15
Æ 
23:13 Oct 31, 2020
H8588
